Bill > SB0055

This bill amends existing Utah law regarding stem cell therapy, specifically focusing on treatments using placental perinatal stem cells or other human cells, tissues, or cellular or tissue-based products, as defined by federal regulations (21 C.F.R. Sec. 1271.3). It allows healthcare providers to perform stem cell therapies not yet approved by the U.S. Food and Drug Administration (FDA) if they provide patients with a specific written notice about the unapproved status of the therapy and encourage consultation with a primary care provider. Furthermore, the bill outlines requirements for suppliers of these cellular products, mandating that they receive written confirmation from the healthcare provider that the required patient notice will be given. The bill also specifies the format and display requirements for this notice, mandates signed patient consent forms detailing the treatment's nature, risks, benefits, and alternatives, and requires the notice to be included in advertisements for the therapy. Exceptions to these requirements exist for providers with FDA approval for investigational drugs or devices, or those performing therapies under contract for accredited institutions. Violations are considered unprofessional conduct, and the bill takes effect on May 6, 2026.